Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_1
1
14%
Ph not_applicable
3
43%
Ph early_phase_1
1
14%
Ph phase_2
2
29%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Terminated3
Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 11 (14.3%)
Phase 22 (28.6%)
N/A3 (42.9%)

Trials by Status

withdrawn114%
terminated343%
completed343%

Recent Activity

0 active trials
Showing 5 of 7
completednot_applicable

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

NCT01967862
terminatedphase_2

NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis

NCT01816048
terminatednot_applicable

Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer

NCT01541358
terminatedphase_1

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02429804
withdrawnnot_applicable

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

NCT02169063
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01967862Not Applicable

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

Completed
NCT01816048Phase 2

NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis

Terminated
NCT01541358Not Applicable

Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer

Terminated
NCT02429804Phase 1

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Terminated
NCT02169063Not Applicable

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

Withdrawn
NCT00936975Phase 2

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Completed
NCT00956163Early Phase 1

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
7